Navigation Links
Investigational Drug Being Pursued for the Treatment of Ischaemic Stroke

Neurobiological Technologies, Inc. (NTI) announced today the presentation of new analysis of data from prior clinical trials of ancrod and updates on the clinical development of their investigational drug, Viprinex(TM) (ancrod), for the treatment of acute ischaemic stroke at the 16th annual European Stroke Congress in Glasgow, Scotland in the United Kingdom. Viprinex is a defibrinogenating agent derived from the venom of the Malayan pit viper.

"The ancrod data presented this week in Glasgow draws positive conclusions that support a new dosing regimen for ancrod and revised inclusion/exclusion criteria for the current clinical trials," said David Sherman, MD, University of Texas Health Science Center at San Antonio, USA.

"The reanalysis enables us to see that ancrod may be safe and effective when administered to patients within six hours of stroke onset. With so few treatments currently available to stroke patients, we look forward to the results of the international phase 3 trials. We hope the phase 3 results provide evidence of definitive safety and efficacy of ancrod in ischaemic stroke in the six-hour time window."

NTI is moving forward with two international, randomized, double-blind, placebo-controlled phase 3 trials for Viprinex(TM) as part of the Ancrod Stroke Program (ASP). These trials, known as ASP-I and ASP-II, will evaluate whether a brief (2 or 3 hour) infusion of ancrod begun up to six hours after onset of stroke can reduce stroke related disability. ASP-I and II are currently enrolling and each trial is planned to enroll 650 patients. Patient accrual began in November 2005.

The trials are being conducted in the U.S., Europe, South Africa, Australia, and New Zealand. Additional countries will be entering the program. The company expects that the trials will be conducted at up to 130 sites worldwide and that approximately 70% of the ASP-I sites and approximately 50% of the ASP-II sites will be lo cated within the U.S. Patients who qualify for enrollment into the clinical trials will receive a two or three-hour intravenous infusion of ancrod or placebo within six hours of stroke onset. If treated within three hours of stroke onset, subjects must have been determined unsuitable for treatment with tPA.

"We have data showing that fibrinogen plays a significant role in influencing stroke outcome. Ancrod directly targets fibrinogen and has the potential to treat strokes by rapidly lowering fibrinogen levels," said David E. Levy, MD, Vice President of Clinical Development for NTI.

"We are aggressively recruiting patients worldwide for the ASP-I and ASP-II studies. We hope by garnering a large patient base for the study we can generate the robust data needed to confirm our new dosing strategy and six hour treatment window for acute ischaemic stroke."


'"/>




Related medicine news :

1. Astrazenecas Investigational Cancer Therapies Revealed at ASCO
2. New Drug Application Submitted for Investigational Antibiotic Doripenem
3. Overweight Kids At Risk Of Being Iron Deficient
4. Solutions Being Sought For Prevention Of Rickets
5. Being Overweight Could Lead To Irregular Heartbeats
6. Being Obese Increases Ones Risk Of A wrong Diagnosis During Medical Imaging
7. Being Obese Could Lead To Kidney Stone Formation
8. Patients Suffering From Severe Mental Diseases Are At Risk Of Being Crime Victims
9. Being together matters, both in marriage and smoking
10. Being Lonely is gene regulated
11. Heart Functions Being Redefined By Researchers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet’s newest campaign, ... standing as living proof that attitude and determination can combine into the most ... spike around the holidays. This campaign will offer patients a new-found hope, by ...
(Date:12/2/2016)... Honolulu, Hawaii (PRWEB) , ... December 02, 2016 ... ... 3, 2016 at the Hyatt Regency Waikiki Beach Resort and Spa in Honolulu, ... (CME) in the field of pain management. , The demand for supplemental ...
(Date:12/2/2016)... California (PRWEB) , ... December 02, 2016 , ... "Pro3rd ... allow FCPX editors to create versatile lower third titles with just a few clicks ... Pro3rd Accents Volume 2 includes 30 lower third animations. Choose from various styles with ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ‘Tis the season ... of $1,000 each from the National Family Partnership and the Drug Enforcement Administration as ... decorated their homes and the 10 winning schools who decorated their campuses with this ...
(Date:11/30/2016)... ... November 30, 2016 , ... Center For Discovery, a nationally ... of a new eating disorder treatment center location in Palm Beach Gardens, Florida.  The ... adolescents, both males and females ages 10 and older with eating disorders, including ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Dec 1, 2016 Research and Markets ... Delivery in Cancer - Technologies, Markets and Companies" to their ... , , ... management of cancer The market value of drug delivery ... estimates from 2015-2025 are given according to organs involved and the ...
(Date:12/2/2016)... Dec. 1, 2016 Around the corners of ... and each habitable land present over earth. Cancer has ... once in a life time this is because of ... until now. Given the steady increase in global cancer ... the spiraling healthcare costs of treatment, there is increasing ...
(Date:12/2/2016)... , Dec. 2, 2016 Allergan plc (NYSE: ... additional information on its previously announced Accelerated Share Repurchase (ASR) ... ... As previously announced, the Company entered into ... which the Company will repurchase $10 billion of its ordinary ...
Breaking Medicine Technology: